1. Home
  2. CFFN vs LTGO Comparison

CFFN vs LTGO Comparison

Compare CFFN & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

HOLD

Current Price

$8.38

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$18.17

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CFFN
LTGO
Founded
1893
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
2010
2026

Fundamental Metrics

Financial Performance
Metric
CFFN
LTGO
Price
$8.38
$18.17
Analyst Decision
Hold
Analyst Count
2
0
Target Price
★ $7.25
N/A
AVG Volume (30 Days)
★ 742.4K
239.0K
Earning Date
04-29-2026
N/A
Dividend Yield
★ 4.51%
N/A
EPS Growth
★ 79.31
N/A
EPS
★ 0.51
N/A
Revenue
★ $16,300,000.00
N/A
Revenue This Year
$20.16
N/A
Revenue Next Year
$6.62
N/A
P/E Ratio
$16.38
★ N/A
Revenue Growth
★ 6.54
N/A
52 Week Low
$5.97
$16.19
52 Week High
$9.26
$25.93

Technical Indicators

Market Signals
Indicator
CFFN
LTGO
Relative Strength Index (RSI) 29.91 38.44
Support Level $8.21 N/A
Resistance Level $8.76 $20.49
Average True Range (ATR) 0.17 1.76
MACD -0.05 -0.70
Stochastic Oscillator 0.81 21.78

Price Performance

Historical Comparison
CFFN
LTGO

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: